Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDDO-1614 PK and Bioequivalence Study in Healthy Males
NCT03382314Phase 1Completed
- Sponsor
- Hyundai Pharmaceutical Co., Ltd.
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HDDO-1614 in osteoporosis, sponsored by Hyundai Pharmaceutical Co., Ltd. Started Oct 2017; status: completed.
02
Drugs
HDDO-1614
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT03382314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382314.